Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
(death announced on this date) 25 October – Tommy Callaghan, 78, Scottish football player (Dunfermline Athletic, Celtic, Clydebank) and manager. 2 November – Janey Godley, 63, Scottish stand-up comedian and writer. 10 November – Derrick Grant, 86, Scottish rugby union player (Hawick, national team). 22 November – Kenny Aird, 77, Scottish footballer (St Mirren, St Johnstone, Heart of Midlothian). 28 November – John McNamee, 83, Scottish footballer (Newcastle United, Hibernian, Blackburn Rovers). (death announced on this date) 4 December – John Docherty, 84, Scottish football player (Brentford) and manager (Millwall, Cambridge United). (death announced on this date) 11 December – Alex Edwards, 78, Scottish footballer (Dunfermline Athletic, Hibernian). 28 December – Charlie Wright, 86, Scottish football player (Grimsby Town, Charlton Athletic) and manager (Bolton Wanderers)
== Chemistry == Anastrozole is a nonsteroidal benzyl triazole. It is also known as α,α,α',α'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile. Anastrozole is structurally related to letrozole, fadrozole, and vorozole, with all being classified as azoles.
Of Molecules and Men (Prometheus Books, 2004; original edition 1967) ISBN 1-59102-185-5 Life Itself: Its Origin and Nature (Simon & Schuster, 1981) ISBN 0-671-25562-2 What Mad Pursuit: A Personal View of Scientific Discovery (Basic Books reprint edition, 1990) ISBN 0-465-09138-5 The Astonishing Hypothesis: The Scientific Search for the Soul (Scribner reprint edition, 1995) ISBN 0-684-80158-2 Georg Kreisel: a Few Personal Recollections. In: Kreiseliana: About and Around Georg Kreisel (1996), pp. 25–32. ISBN 1-56881-061-X
Half-Life 2: Lost Coast is an additional level for the 2004 first-person shooter game Half-Life 2. Developed by Valve, it was released on October 27, 2005, as a free download for owners of Half-Life 2 on Steam. Players control Half-Life protagonist Gordon Freeman as he travels up a coastal cliff to destroy a Combine weapon in a monastery. Lost Coast is a technology demonstration showcasing the high-dynamic-range rendering implemented in the Source engine. It was designed with environments to emphasize these effects. Lost Coast was the first Valve game with a commentary mode, in which the developers explain elements of design as the player progresses through the level. The Lost Coast level was created for Half-Life 2, but was removed from the game. It was originally going to be a level in "Highway 17" where Gordon ends up in a strange place meeting a Fisherman. As a result, it has several minor story details that were not included in Half-Life 2. It received a generally positive reception, and there was consensus among reviewers that the new features included in Lost Coast should be integrated into future games released by Valve.
Sauvagine is a neuropeptide from the corticotropin-releasing factor (CRF) family of peptides and is orthologous to the mammalian hormone, urocortin 1, and the teleost fish hormone, urotensin 1. It is 40 amino acids in length, and has the sequence XGPPISIDLSLELLRKMIEIEKQEKEKQQAANNRLLLDTI-NH2, with a pyrrolidone carboxylic acid modification at the N-terminal and amidation of the C-terminal isoleucine residue. It was originally isolated from the skin of the frog Phyllomedusa sauvagii. Given its relation to other CRF-related peptides, it exerts similar physiological effects as corticotropin-releasing hormone. Sauvagine belongs to the corticotropin-releasing factor (CRF) family that also includes CRF, urocortin l/urotensin l, urocortin II and urocortin III.
Sources: en.wikipedia.org
== Registration of PKMM rejected == In 1950, the Federation of Malaya Government rejected the registration of the Malay Nationalist Party of Malaya (Parti Kebangsaan Melayu Malaya, PKMM) as a legitimate political party. PKMM had two wings, namely Angkatan Pemuda Insaf and Angkatan Wanita Sedar. Initially, PKMM did not have communist leanings. After Mokhtaruddin Lasso was elected as the first PKMM president in October 1946, this party was influenced with communism. The Young Malays Union (Kesatuan Melayu Muda, KMM) merged with PKMM, and Burhanuddin al-Helmy became the second PKMM president. Burhanuddin led PKMM toward the formation of Melayu Raya, a merger of Indonesia and Malaya. In December 1947, Ishak Haji Mohamed became the third PKMM president and PKMM switched from communism to nationalism. PKMM tended against United Malays National Organisation (UMNO) and colonisation. PKKM established the Pusat Tenaga Rakyat (PUTERA), a conglomeration of radical Malay Political Parties and then merged with the All-Malaya Council of Joint Action (AMCJA) which thoroughly opposed the 1948 Federation Agreement for the foundation of the Federation of Malaya. PKMM accused officials selected in the Federation of Malaya of being "puppets" of the "Colonial Office". For PKMM, there was no basis in "preparing Malaya as a democratic government".
The reef is seeded with young abalone from an onshore hatchery. The abalone feed on seaweed that has grown naturally on the habitats, with the ecosystem enrichment of the bay also resulting in growing numbers of dhufish, pink snapper, wrasse, and Samson fish, among other species. Brad Adams, from the company, has emphasised the similarity to wild abalone and the difference from shore-based aquaculture. "We're not aquaculture, we're ranching, because once they're in the water they look after themselves."
The abdication of Kings Charles IV of Spain and Ferdinand VII of Spain and the installation of Napoleon's brother as King José provoked civil wars and revolutions, leading to the independence of most of Spain's mainland American colonies. In Spanish America, many local elites formed juntas and set up mechanisms to rule in the name of Ferdinand VII, whom they considered the legitimate Spanish monarch. The outbreak of the Spanish American wars of independence in most of the empire was a result of Napoleon's destabilizing actions in Spain, and led to the rise of strongmen in the wake of these wars. The defeat of Napoleon at Waterloo in 1815 caused an exodus of French soldiers into Latin America, where they joined ranks with the armies of the independence movements. While these officials had a role in various victories such as the Capture of Valdivia (1820), some are held responsible for significant defeats at the hands of the royalists, as was the case at the Second Battle of Cancha Rayada (1818). In contrast, the Portuguese royal family escaped to Brazil and established the court there, resulting in political stability for Portuguese America. In 1816, Brazil was proclaimed an equal part of the United Kingdom of Portugal, Brazil and the Algarves, paving the way to Brazilian independence six years later.
=== MeSH D12.644.548 – peptide hormones === MeSH D12.644.548.009 – activins MeSH D12.644.548.009.500 – inhibin-beta subunits MeSH D12.644.548.014 – adiponectin MeSH D12.644.548.020 – atrial natriuretic factor MeSH D12.644.548.100 – bombesin MeSH D12.644.548.150 – calcitonin MeSH D12.644.548.200 – corticotropin-releasing hormone MeSH D12.644.548.275 – gastric inhibitory polypeptide MeSH D12.644.548.280 – gastrins MeSH D12.644.548.343 – glucagon precursors MeSH D12.644.548.343.249 – enteroglucagons MeSH D12.644.548.343.249.500 – glucagon-like peptide 1 MeSH D12.644.548.343.500 – glucagon MeSH D12.644.548.387 – inhibins MeSH D12.644.548.387.500 – inhibin-beta subunits MeSH D12.644.548.393 – insulin MeSH D12.644.548.393.408 – insulin, isophane MeSH D12.644.548.393.532 – insulin, long-acting MeSH D12.644.548.393.788 – proinsulin MeSH D12.644.548.393.788.250 – c-peptide MeSH D12.644.548.400 – leptin MeSH D12.644.548.500 – motilin MeSH D12.644.548.560 – msh release-inhibiting hormone MeSH D12.644.548.580 – msh-releasing hormone MeSH D12.644.548.585 – natriuretic peptide, c-type MeSH D12.644.548.587 – pancreatic polypeptide MeSH D12.644.548.588 – parathyroid hormone-related protein MeSH D12.644.548.590 – parathyroid hormone MeSH D12.644.548.590.850 – teriparatide MeSH D12.644.548.592 – peptide phi MeSH D12.644.548.595 – peptide yy MeSH D12.644.548.600 – pituitary hormone release inhibiting hormones MeSH D12.644.548.620 – pituitary hormone-releasing hormones MeSH D12.644.548.691 – pituitary hormones MeSH D12.644.548.691.525 – pituitary hormones, anterior MeSH D12.644.548.691.525.343 – gonadotropins, pituitary MeSH D12.644.548.691.525.343.288 – follicle stimulating hormone MeSH D12.644.548.691.525.343.288.500 – follicle stimulating hormone, beta subunit MeSH D12.644.548.691.525.343.288.750 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.343.463 – luteinizing hormone MeSH D12.644.548.691.525.343.463.249 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.343.463.500 – luteinizing hormone, beta subunit MeSH D12.644.548.691.525.343.583 – menotropins MeSH D12.644.548.691.525.343.583.500 – urofollitropin MeSH D12.644.548.691.525.425 – growth hormone MeSH D12.644.548.691.525.425.875 – human growth hormone MeSH D12.644.548.691.525.525 – prolactin MeSH D12.644.548.691.525.690 – pro-opiomelanocortin MeSH D12.644.548.691.525.690.130 – corticotropin MeSH D12.644.548.691.525.690.130.050 – alpha-msh MeSH D12.644.548.691.525.690.130.200 – cosyntropin MeSH D12.644.548.691.525.690.480 – lipotropin MeSH D12.644.548.691.525.690.583 – melanocyte-stimulating hormones MeSH D12.644.548.691.525.690.583.050 – alpha-msh MeSH D12.644.548.691.525.690.583.075 – beta-msh MeSH D12.644.548.691.525.690.583.115 – gamma-msh MeSH D12.644.548.691.525.883 – thyrotropin MeSH D12.644.548.691.525.883.249 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.883.500 – thyrotropin, beta subunit MeSH D12.644.548.691.692 – pituitary hormones, posterior MeSH D12.644.548.691.692.433 – oxytocin MeSH D12.644.548.691.692.781 – vasopressins MeSH D12.644.548.691.692.781.100 – argipressin MeSH D12.644.548.691.692.781.100.250 – deamino arginine vasopressin MeSH D12.644.548.691.692.781.400 – lypressin MeSH D12.644.548.691.692.781.400.350 – felypressin MeSH D12.644.548.691.692.781.700 – ornipressin MeSH D12.644.548.691.692.881 – vasotocin MeSH D12.644.548.726 – placental hormones MeSH D12.644.548.726.367 – chorionic gonadotropin MeSH D12.644.548.726.367.125 – chorionic gonadotropin, beta subunit, human MeSH D12.644.548.726.367.562 – glycoprotein hormones, alpha subunit MeSH D12.644.548.726.451 – gonadotropins, equine MeSH D12.644.548.726.692 – placental lactogen MeSH D12.644.548.762 – relaxin MeSH D12.644.548.786 – resistin MeSH D12.644.548.810 – secretin MeSH D12.644.548.857 – somatostatin MeSH D12.644.548.869 – thymosin MeSH D12.644.548.905 – urotensins MeSH D12.644.548.952 – vasoactive intestinal peptide
=== Animal-derived === Some drugs used in modern medicine have been discovered in animals or are based on compounds found in animals. For example, the anticoagulant drugs, hirudin and its synthetic congener, bivalirudin, are based on saliva chemistry of the leech, Hirudo medicinalis. Used to treat type 2 diabetes, exenatide was developed from saliva compounds of the Gila monster, a venomous lizard.
Sources: en.wikipedia.org
=== Spectrum of susceptibility === Vancomycin is a last-resort medication for the treatment of sepsis and lower respiratory tract, skin, and bone infections caused by Gram-positive bacteria. The minimum inhibitory concentration susceptibility data for a few medically significant bacteria are:
== Molecular properties and chemical space of peptides == The chemical space of peptides is defined as a multidimensional landscape shaped by molecular descriptors or fingerprints. Within these frameworks, the distance between specific molecules serves as a proxy for chemical or functional similarity. This space can be mapped using primary amino acid sequences, three-dimensional structural data, or a combination of both. Key molecular properties used for mapping include molecular weight, lipophilicity (logP and logD), topological polar surface area (TPSA), and hydrogen-bond dynamics. Dimensionality-reduction techniques—such as Principal Component Analysis (PCA), t-SNE, and UMAP—are frequently employed alongside clustering algorithms to visualize peptide libraries and identify clusters with related biological activities. Peptides are distinguished from traditional small molecules by their unique combination of residue sequence, amide backbone flexibility, and susceptibility to chemical modifications, all of which dictate bioavailability and membrane permeability. Computational analysis is supported by notation systems like FASTA, HELM, and BILN for encoding both canonical and modified sequences. Modifications such as cyclization or the integration of non-natural amino acids significantly shift a peptide's position within the chemical space, altering its stability and target affinity. Consequently, chemical-space analysis is a vital tool for virtual screening and the discovery of shared bioactivity regions across different peptide families.
The news reportedly left palaeontologist John Ostrom, who in the 1970s had pioneered the theory that birds evolved from dinosaurs, "in a state of shock." Ostrom later joined an international team of researchers who gathered in Beijing to examine the fossils; other team members included feather expert Alan Brush, fossil bird expert Larry Martin, and Peter Wellnhofer, an expert on the early bird Archaeopteryx. Three specimens have been assigned to Sinosauropteryx prima: the holotype GMV 2123 (and its counter slab [opposite face], NIGP 127586), NIGP 127587, and D 2141. Another specimen, IVPP V14202, was originally assigned to the genus in 2010, but was later designated as the holotype of a separate genus Huadanosaurus. The assignment of an additional larger specimen to S. prima, GMV 2124 (also known as NGMC 2124), was later found to be in error, and most likely belongs to Tyrannosauroidea. All of the fossils were found in the Jianshangou or Dawangzhangzi Beds of the Yixian Formation in the Beipiao and Lingyuan regions of Liaoning, China. These fossil beds have been dated to 124.6–122 million years ago, during the early Aptian stage of the Early Cretaceous.
She has released two albums on the Karaoke Kalk label: Kids with Sticks in 2001 and the collaboration Kuchen Meets Mapstation in 2003 with Stefan Schneider of To Rococo Rot (who also records as Mapstation). Horner is a film producer based in Newcastle upon Tyne. Browne went on to play with Warm Jets, Rialto, and White Hotel (with Jean-Marc Butty, longtime drummer for PJ Harvey) before briefly returning to Canada in 2001, then relocating to San Francisco in 2002. There she played with local rock noir chanteuse Rykarda Parasol, appearing on her Here She Comes EP and the Our Hearts First Meet album, then went on to record and tour with The Wronglers, an old-time band with Warren Hellman, founder and financer of San Francisco's free Hardly Strictly Bluegrass festival, who also made an album with Jimmie Dale Gilmore called "Heirloom Music".
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.